<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-90194</identifier>
<setSpec>0212-6567</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in Primary Care</dc:title>
<dc:description xml:lang="en">Objective: The objective of this study was to estimate the continuous abstinence rates of varenicline, bupropion and nicotine replacement therapy (NRT) in smoking cessation in 2 Primary Care (PC) External Support Units.DesignObservational, multicentre, longitudinal study using a retrospective review of medical records.SettingSix Primary Care Centres.ParticipantsPatients &gt; 18 years, who began smoking cessation treatment between 1/01/2006 and 1/12/2008 with varenicline, bupropion or NRT were included in the analysis.ContinuationPatient follow-up was conducted from time-baseline (day 1) and assessed at 6 and 12 months. Main variables: comorbidities, effectiveness (continuous abstinence) and pharmacological tolerability. Statistical analysis: logistic regression models and Kaplan-Maier survival curves; P&lt;.05.ResultsA total of 957 smokers treated with NRT (53.0%), bupropion (25.1%) and varenicline (21.9%) were included in the analysis. Mean age: 47.6 (11.3) years; 58.6% men. 32.0% of smokers attended due to physical dependence. Average duration of smoking: 19.5 (6.7) years. At 6 months, 61.2% (95% CI: 54.6-67.8%) of participants in the varenicline group continuously abstained from smoking compared with 56.9% (95% CI: 50.6-63.2%) in the bupropion group, and 52.3% (95% CI: 48.0-56.6%) in the NRT group; P=.003. At 12 months, the rate of continuous abstinence was 57.4% (95% CI: 50.7-64.1%) in the varenicline group compared with 52.9% (95% CI: 46.6-59.2%) in the bupropion group and 47.1% (95% CI: 42.8-51.4%) in the NRT group; P=.002.ConclusionOne year-follow up results suggest that varenicline is an appropriate alternative compared with bupropion and NRT on smoking cessation in the PC setting(AU)</dc:description>
<dc:creator>Díaz Cerezo, Silvia</dc:creator>
<dc:creator>Sicras Mainar, Antoni</dc:creator>
<dc:creator>Martí Sánchez, Belén</dc:creator>
<dc:creator>Navarro Artieda, Ruth</dc:creator>
<dc:creator>Sanz De Burgoa, Verónica</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Determinar las tasas de abstinencia continua conseguidas con vareniclina, bupropión y terapia de sustitución nicotínica (TSN) en la cesación del consumo de tabaco en 2 unidades externas de apoyo a atención primaria (AP).DiseñoEstudio observacional, multicéntrico, longitudinal, a partir de la revisión retrospectiva de registros médicos.EmplazamientoSeis centros de AP.ParticipantesSe incluyeron pacientes &gt; 18 años que iniciaron tratamiento de cesación del hábito tabáquico entre 1/01/2006 y 31/12/2008 con vareniclina, bupropión o TSN.Mediciones principalesPrincipales medidas: sociodemográficas, comorbilidad, efectividad (abstinencia continua) y tolerabilidad farmacológica. Se evaluó la abstinencia a los 6 y 12 meses de seguimiento. Análisis estadístico: modelos de regresión logística y curva de supervivencia de Kaplan-Meier.ResultadosSe incluyeron 957 pacientes fumadores, tratados con TSN (53,0%), bupropión (25,1%) y vareniclina (21,9%). Su media de edad era 47,6 (DE: 11,3) años, y el 58,6% eran hombres. Un 32,0% acudieron por dependencia física y el tiempo medio de fumadores fue de 19,5 (DE: 6,7) años. A los 6 meses, la abstinencia continua con vareniclina fue del 61,2% (IC: 54,6-67,8%), con bupropión del 56,9% (IC: 50,6-63,2%) y con TSN del 52,3% (IC: 48,0-56,6%); p=0,003. A los 12 meses, fue del 57,4% (IC: 50,7-64,1%), 52,9% (IC: 46,6-59,2%) y 47,1% (IC: 42,8-51,4%), respectivamente, p=0,002.ConclusionesLos resultados tras un año de seguimiento sugieren que vareniclina es una alternativa adecuada frente al bupropión y la TSN en la cesación del tabaco en el ámbito de la AP(AU)</dc:description>
<dc:source>Aten Primaria;43(9): 482-489, sept. 2011.</dc:source>
<dc:identifier>ibc-90194</dc:identifier>
<dc:title xml:lang="es">Tasas de abstinencia de vareniclina frente a bupropión y terapia sustitutiva con nicotina en la cesación del tabaco en atención primaria</dc:title>
<dc:subject>^d9723</dc:subject>
<dc:subject>^d14418^s22018</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d23925^s22054</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d23925^s22053</dc:subject>
<dc:subject>^d23925^s22034</dc:subject>
<dc:subject>^d23925^s22056</dc:subject>
<dc:subject>^d14418^s22056</dc:subject>
<dc:subject>^d14418^s22024</dc:subject>
<dc:subject>^d14418^s22016</dc:subject>
<dc:subject>^d9723^s22048</dc:subject>
<dc:subject>^d14418^s22028</dc:subject>
<dc:subject>^d23925^s22018</dc:subject>
<dc:subject>^d23925^s22028</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d9723^s22000</dc:subject>
<dc:subject>^d14418^s22053</dc:subject>
<dc:type>article</dc:type>
<dc:date>201109</dc:date>
</metadata>
</record>
</ibecs-document>
